Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.4 USD | -1.30% | -0.26% | +42.68% |
07/05 | AstraZeneca target raised; Antofagasta lowered | AN |
03/05 | AIB buys back EUR999 million worth of shares from Irish government | AN |
Sales 2024 * | 455.65Cr 490.6Cr 41TCr | Sales 2025 * | 434.04Cr 467.33Cr 39TCr | Capitalization | 1.24TCr 1.34TCr 1,11400Cr |
---|---|---|---|---|---|
Net income 2024 * | 176.2Cr 189.71Cr 16TCr | Net income 2025 * | 156.1Cr 168.07Cr 14TCr | EV / Sales 2024 * | 2.72 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.86 x |
P/E ratio 2024 * |
7.11
x | P/E ratio 2025 * |
7.4
x | Employees | 10,551 |
Yield 2024 * |
5.89% | Yield 2025 * |
6.25% | Free-Float | 68.01% |
Latest transcript on AIB Group plc
1 day | -1.30% | ||
1 week | -0.26% | ||
Current month | +0.26% | ||
1 month | +5.95% | ||
3 months | +7.45% | ||
6 months | +39.88% | ||
Current year | +42.68% |
Managers | Title | Age | Since |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 01/16/01 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 01/13/01 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 19/23/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Pettigrew
CHM | Chairman | 65 | 28/21/28 |
Basil Geoghegan
BRD | Director/Board Member | - | 04/19/04 |
Colin Hunt
CEO | Chief Executive Officer | 54 | 01/16/01 |
Date | Price | Change | Volume |
---|---|---|---|
06/24/06 | 11.55 | +5.24% | 1,536 |
05/24/05 | 10.98 | -3.98% | 2,362 |
Delayed Quote OTC Markets, June 11, 2024 at 01:11 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.35% | 57TCr | |
+17.82% | 31TCr | |
+15.71% | 25TCr | |
+17.70% | 20TCr | |
+21.72% | 18TCr | |
+27.18% | 17TCr | |
+9.14% | 16TCr | |
+9.11% | 15TCr | |
-8.66% | 14TCr |
- Stock Market
- Equities
- A5G Stock
- AIBGY Stock